Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00239720 · ClinicalTrials.gov registry record · Phase 2
PsA Treatment With hOKT3γ1 (Ala-Ala)
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00239720 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 4 participants.
The verdict
NCT00239720, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
hOKT3gamma1 (Ala-Ala) is a man-made antibody that is commonly used to prevent organ rejection. The purpose of this study is to determine whether hOKT3gamma1 (Ala-Ala) is safe and effective in psoriatic arthritis patients who are unable to control their arthritis with methotrexate or azathioprine.
Interventions
- DRUG Placebo
- DRUG hOKT3gamma1(Ala-Ala)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-03-16 |
| Est. Completion | 2008-06-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00239720
The ClinicalTrials.gov registry entry for NCT00239720 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00239720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00239720 about?
NCT00239720 is a clinical study titled "PsA Treatment With hOKT3γ1 (Ala-Ala)". hOKT3gamma1 (Ala-Ala) is a man-made antibody that is commonly used to prevent organ rejection. The purpose of this study is to determine whether hOKT3gamma1 (Ala-Ala) is safe and effective in psoriatic arthritis patients who are unable to control their arthritis with methotrexate or azathioprine.
What is the current status of trial NCT00239720?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2006-03-16. Estimated completion is 2008-06-25.
What interventions are being tested in trial NCT00239720?
The interventions under investigation include: Placebo (DRUG), hOKT3gamma1(Ala-Ala) (DRUG).
Who is sponsoring clinical trial NCT00239720?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.